Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07288801

Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women

Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
146 (estimated)
Sponsor
Nishtar Medical University · Academic / Other
Sex
Female
Age
20 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is: Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia? To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study. Participants will be randomly assigned to two equal groups: * Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation. * Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D. While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded. At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia. This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.

Conditions

Interventions

TypeNameDescription
DRUGVitamin D4000 IU of vitamin D will be given orally, once daily till 36-weeks of gestation
DRUGPlacebo and standard of careLook, smell and taste alike oil emulsion drops, same number, till 36-weeks of gestation

Timeline

Start date
2025-08-09
Primary completion
2026-02-08
Completion
2026-02-08
First posted
2025-12-17
Last updated
2025-12-17

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07288801. Inclusion in this directory is not an endorsement.